Lv1
56 积分 2020-12-07 加入
Safety, pharmacokinetics and pharmacodynamics of multiple‐dose noiiglutide (SHR20004), a novel GLP‐1 receptor agonist, in Chinese obese subjects without diabetes mellitus
12小时前
待确认
Electroencephalography (EEG) spectral signatures of selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs) and vortioxetine in major depressive disorder: A systematic review
4个月前
已完结
Effects of lorazepam on saccadic eye movements – evidence from prosaccade and free viewing tasks
9个月前
已完结
Administration of oxathridine, a first‐in‐class histamine‐3 receptor partial agonist in healthy male volunteers: Central nervous system depression and pseudo‐hallucinations
9个月前
已完结
Eye Movement in Neurological Disorders
10个月前
已完结
Video-oculography eye tracking towards clinical applications: A review
11个月前
已完结
Efficacy of noiiglutide injection on body weight in obese Chinese adults without diabetes: A multicentre, randomized, double‐blind, placebo‐controlled, phase 2 trial
11个月前
已完结
Comparison of 10-mg Doses of 4-Aminopyridine and 3,4-Diaminopyridine for the Treatment of Downbeat Nystagmus
11个月前
已关闭
Safety, pharmacokinetics and pharmacodynamics of HRS‐7535, a novel oral small molecule glucagon‐like peptide‐1 receptor agonist, in healthy participants: A phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose, and food effect trial
1年前
已完结
Orforglipron (LY3502970), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1a, blinded, placebo‐controlled, randomized, single‐ and multiple‐ascending‐dose study in healthy participants
1年前
已完结
皖公网安备34019202002308
